VISCHER’s advised Genedata on the deal. Genedata AG, a leading provider of software solutions for biopharmaceutical R&D, has been acquired by Danaher Corporation (NYSE: DHR), a...
You must be a Standard 1 Year member to access this content.
VISCHER AG acted for Odne on the deal. Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch for...
You must be a Standard 1 Year member to access this content.
Vischer advised GlycoEra AG on the deal. GlycoEra AG has closed CHF 45m (USD 49m) Series A financing round, co-led by re-nowned US and European life...
You must be a Standard 1 Year member to access this content.
VISCHER advised Proteomedix on the deal. Proteomedix AG, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech, Inc. (Nasdaq: BWV) are forming together a company...
You must be a Standard 1 Year member to access this content.
VISCHER advised Evorest AG on all Swiss legal issues related to the launch of the business, including incorporation, pre-seed financing, contractual and regulatory work. Evorest AG...
You must be a Standard 1 Year member to access this content.
VISCHER advises Mosanna Therapeutics on the deal. Mosanna Therapeutics AG closes an extension of the Seed Financing Round with the investors Supermoon Capital and High-Tech Gründerfonds...
You must be a Standard 1 Year member to access this content.
Vischer advised Resistell AG on the deal. Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another...
You must be a Standard 1 Year member to access this content.
VISCHER advised Mosanna Therapeutics AG on the deal. Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for...
You must be a Standard 1 Year member to access this content.
VISCHER advised Novaremed AG on the deal. Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience...
You must be a Standard 1 Year member to access this content.
Lenz & Staehelin advised co-lead investors Samsara Biocapital and Lightspeed Venture Partners as their Swiss counsel. VISCHER advised ImmunOs. Walder Wyss advises Gimv. ImmunOs Therapeutics AG,...
You must be a Standard 1 Year member to access this content.
Walder Wyss acted as Swiss legal counsel for Alloy Therapeutics Inc on the deal. Vischer advised deepCDR Biologics AG. Alloy Therapeutics, a biotechnology ecosystem company, acquired...
You must be a Standard 1 Year member to access this content.
Vischer advised GlycoEra AG on the deal. Walder Wyss advised 5AM Ventures, Roche Venture Fund and Sofinnova Partners as lead investors. GlycoEra AG has closed CHF...
You must be a Standard 1 Year member to access this content.
